CN112656874A - Composition for improving function of vascular endothelial cells and application thereof - Google Patents
Composition for improving function of vascular endothelial cells and application thereof Download PDFInfo
- Publication number
- CN112656874A CN112656874A CN202011623645.2A CN202011623645A CN112656874A CN 112656874 A CN112656874 A CN 112656874A CN 202011623645 A CN202011623645 A CN 202011623645A CN 112656874 A CN112656874 A CN 112656874A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- vascular endothelial
- improving
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to a composition for improving the function of vascular endothelial cells and application thereof. The composition is prepared from the following substances in parts by weight: 10-20 parts of giant knotweed extract, 10-20 parts of grape seed extract and 1-3 parts of arginine. The invention utilizes resveratrol in the giant knotweed rhizome extract and procyanidine in the grape seed extract to remove free radicals, has strong antioxidation and protects vascular endothelial cells from being damaged; arginine is utilized to maintain the vasodilation function of blood vessels; the composition can remarkably repair damaged vascular endothelium, recover its contraction and relaxation function, and improve endothelial cell function, so as to improve cardiovascular diseases such as atherosclerosis and hypertension.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a composition for improving the function of vascular endothelial cells and application thereof.
Background
Vascular Endothelial Cells (VECs) are a layer of flat squamous cells which continuously cover the entire vascular luminal surface, and regulate the permeability of the vascular wall in ways of adjustment and contraction and the like through self structures (such as tight connection and adhesive connection). The physiological functions also include: regulating the permeability of the vascular wall and maintaining the blood coagulation function balance and the blood flow state; maintaining vascular architecture and smooth muscle tone to maintain vasoconstrictive and diastolic balance; regulating angiogenesis and cell proliferation; mediate inflammation and immune responses; inhibiting the adhesion and aggregation of inflammatory cells. The main substances secreted by VEC include endothelium-dependent contraction factors such as endothelin, angiotensin Il and thromboxane a2, endothelium-dependent relaxation factors such as nitric oxide, prostacyclin, bradykinin and endothelium-dependent hyperpolarizing factor, and bioactive substances such as interleukins, tissue plasminogen activators, plasminogen inhibitors and von willebrand factor.
VECs play an important role in the development, progression and terminal stages of cardiovascular disease and its related diseases. The cardiovascular and cerebrovascular disease prediction index is a target organ acted by various cardiovascular and cerebrovascular diseases or risk factors, endothelial function damage is frequently accompanied and aggravated, vascular endothelial dysfunction is related to a series of diseases and states such as atherosclerosis and hypertension, and the cardiovascular and cerebrovascular disease prediction index is the earliest change of atherosclerosis and is an independent prediction index for future cardiovascular event increase of patients with coronary heart disease.
At present, drugs aiming at atherosclerosis, mainly statins and anti-platelet aggregation drugs (such as aspirin enteric-coated tablets, clopidogrel and the like) are available in the market, and few specific products aiming at vascular endothelial repair are available. Statins often cause hepatotoxicity and kidney toxicity, and anti-platelet aggregation drugs often cause internal hemorrhage, moreover, the pathogenesis of atherosclerosis is various, and broad-spectrum treatment drugs have no good treatment effect. Therefore, there is a need for the development of a highly safe drug that specifically improves vascular endothelial cells.
Disclosure of Invention
In order to solve the technical problems, the invention provides a composition for improving the function of vascular endothelial cells and application thereof.
The invention aims to provide a composition for improving the function of vascular endothelial cells, which is prepared from the following substances in parts by weight: 10-20 parts of giant knotweed extract, 10-20 parts of grape seed extract and 1-3 parts of arginine.
Preferably, in the composition for improving vascular endothelial cell function, the effective component of the polygonum cuspidatum extract is resveratrol, and the content of resveratrol is more than or equal to 50 wt%.
Preferably, in the composition for improving vascular endothelial cell function, the grape seed extract contains procyanidin as an active ingredient, and the content of procyanidin is greater than or equal to 95 wt%.
Preferably, the composition for improving the function of the vascular endothelial cells further comprises one or more of ginkgo leaves, pseudo-ginseng and salvia miltiorrhiza, and the addition amount of the ginkgo leaves, the pseudo-ginseng or the salvia miltiorrhiza is 3-5 parts.
Preferably, the composition for improving the function of the vascular endothelial cells further comprises one or more of hawthorn, fish oil powder and red yeast rice, and the addition amount of the hawthorn, the fish oil powder or the red yeast rice is 3-5 parts.
Preferably, the composition for improving the function of the vascular endothelial cells is prepared into a pharmaceutically acceptable dosage form.
Preferably, the pharmaceutical dosage form of the composition for improving vascular endothelial cell function is tablet, granule or powder.
The invention also provides application of the composition for improving the function of the vascular endothelial cells in preparing a medicament for preventing and treating cardiovascular and cerebrovascular diseases.
The invention also provides application of the polygonum cuspidatum extract in preparing a medicine for improving the function of vascular endothelial cells.
The invention also provides application of the grape seed extract in preparing a medicine for improving the function of vascular endothelial cells.
Compared with the prior art, the invention has the following beneficial effects:
the invention utilizes resveratrol in the giant knotweed rhizome extract and procyanidine in the grape seed extract to remove free radicals, has strong antioxidation and protects vascular endothelial cells from being damaged. Arginine is a raw material for endothelial cells to synthesize endothelial dependent relaxation factor/nitric oxide, and plays an important role in maintaining the vasodilation function of blood vessels. The giant knotweed rhizome extract, the grape seed extract and the arginine are combined to promote the generation of NO, reduce the expression of NF-kB and vasoconstrictor ET-1 (endothelin), can remarkably repair damaged vascular endothelium, recover the contraction and relaxation functions of the vascular endothelium, improve the function of endothelial cells, further improve cardiovascular diseases such as atherosclerosis, hypertension and the like, and further promote the health of blood vessels.
The composition disclosed by the invention adopts common traditional Chinese medicines and dietary supplements as raw materials, is orally taken and absorbed by small intestines, has an obvious effect, and effectively avoids side effects of simvastatin and other medicaments. The invention aims to improve the function of vascular endothelium and provides reference for the treatment of cardiovascular diseases such as arteriosclerosis, hypertension and the like.
In order to improve the blood circulation promoting effect of the composition, blood circulation promoting raw materials such as ginkgo leaves, pseudo-ginseng, red sage roots and the like or blood fat reducing components such as hawthorn, fish oil powder, red yeast rice and the like can be added to improve the function improving effect of vascular endothelial cells after the giant knotweed rhizome extract, the grape seed extract and the arginine are combined.
Detailed Description
In order that those skilled in the art will better understand the technical solutions of the present invention to practice, the present invention will be further described with reference to the following specific examples.
In the following examples, reagents and experimental methods used are conventional methods unless otherwise specified; the polygonum cuspidatum extract and the grape seed extract are purchased from Shanxi ang warming Biotechnology GmbH; the common feed is from the experimental animal center of the university of military medical science of air force; the high-fat feed is prepared by uniformly mixing 75 wt% of common feed, 8 wt% of grass meal, 10 wt% of egg yolk, 5 wt% of lard and 2 wt% of cholesterol; the adopted Nitric Oxide (NO) determination kit is purchased from Shanghai Huzhen Biotechnology Limited; the adopted ELISA kit ET-1 and NF-kB are from Shanghai future industry Co Ltd; the unbalanced method kit for ET-1 determination comes from the exemption research institute of the science and technology development center of the general hospital of the people's liberation army in China. In the following examples, one part by weight corresponds to 1g by mass.
Example 1
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract and 3 parts of arginine.
The preparation method of the composition for improving the function of the vascular endothelial cells of the embodiment is as follows:
weighing the raw materials according to the parts by weight, weighing 10 parts of resistant dextrin, respectively sieving the raw materials with a 100-mesh sieve, uniformly mixing, adding ethanol solution with the volume concentration of 75% and the total weight of 15%, granulating, drying at 55 ℃ for 3h, sieving with a 14-mesh sieve, grading, adding magnesium stearate with the mass fraction of 0.5%, uniformly mixing, and pressing into tablets with the mass fraction of 0.6 g/tablet.
Example 2
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 10 parts of giant knotweed extract, 10 parts of grape seed extract and 2 parts of arginine. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 3
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 20 parts of giant knotweed extract, 20 parts of grape seed extract and 1 part of arginine. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 4
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine, 3 parts of ginkgo leaf, 3 parts of pseudo-ginseng and 3 parts of salvia miltiorrhiza. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 5
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 4 parts of pseudo-ginseng, 3 parts of ginkgo leaf and 5 parts of salvia miltiorrhiza. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 6
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 20 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine, 4 parts of ginkgo leaf and 4 parts of pseudo-ginseng. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 7
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 3 parts of pseudo-ginseng and 3 parts of salvia miltiorrhiza. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 8
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 4 parts of salvia miltiorrhiza and 4 parts of ginkgo leaf. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 9
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine and 5 parts of salvia miltiorrhiza. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 10
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine and 5 parts of ginkgo leaf. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 11
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine and 5 parts of pseudo-ginseng. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 12
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine and 5 parts of hawthorn. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 13
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine and 5 parts of fish oil powder. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 14
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 15 parts of grape seed extract, 3 parts of arginine and 5 parts of red yeast rice. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 15
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 4 parts of hawthorn and 4 parts of fish oil powder. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 16
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 4 parts of hawthorn and 4 parts of red yeast rice. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 17
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 4 parts of fish oil powder and 5 parts of red yeast rice. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Example 18
A composition for improving the function of vascular endothelial cells is prepared from the following substances in parts by weight: 15 parts of giant knotweed extract, 20 parts of grape seed extract, 3 parts of arginine, 3 parts of hawthorn, 3 parts of fish oil powder and 3 parts of red yeast rice. The method of preparing the drug of this example was substantially the same as in example 1, except that the drug formulation was replaced with the formulation of this example.
Experimental example 1 metabolites of vascular endothelial cells before and after animal experiment treatment
60 golden yellow hamster, half of female, body weight 80 + -5 g. After the golden-yellow hamster is fed with the common feed adaptively for 1 week, the golden-yellow hamster is randomly divided into 6 groups according to the body weight, 10 groups of the golden-yellow hamster are divided into a control group, a high fat group, a giant knotweed extract group, a grape seed extract group, an arginine group and a mixed group of the three groups (the giant knotweed extract: the grape seed extract: arginine is 5:5: 1: w/w), the feeding environment temperature is 22 +/-3 ℃, the humidity is 60%, the illumination is 12h, and the darkness is 12 h. Except for the control group which eat common feed, 5 groups are all fed with high-fat feed. The test subjects were gavaged in each group at 4g/kg bw while molding, in the control group and the high fat group at the same amount of tap water, once a day for 8w continuously, animals were allowed to eat and drink water freely during the test period, and the rats in each group were fed once a day at 10 am. Groups of golden hamster were weighed once a week.
At the end of 8 weeks of the gavage, the golden hamster was fasted for 12h, anesthetized by intraperitoneal injection of 10% urethane at 1.0g/kg bw, 2ml of blood was taken from orbital venous plexus, injected into a test tube containing 10g/100ml of disodium edta and 40ml of aprotinin, mixed well, centrifuged at 4 ℃, 3000r/min, 10min, plasma was separated and stored at-20 ℃. Redissolving at room temperature before measurement, centrifuging at 4 deg.C for 5min at 3000r/min, and collecting supernatant for measurement.
And (3) determining the NO content by adopting a nitric acid reductase method of a nitric oxide determination kit. Performing ET-1 determination by adopting a non-equilibrium method kit; and detecting NF-kappa B by adopting an ELISA kit. Sampling method the same nitric oxide measurement.
TABLE 1 comparison of vascular endothelial cell metabolites before and after animal experimental treatment
Note: p <0.05 compared to high fat group; compared with the mixed group of the three components, # P <0.05
As can be seen from Table 1 above, all groups raised the plasma NO level of golden hamster and reduced the levels of ET-1 and NF-. kappa.B compared to the high fat group at the end of week 8 of the experiment. Meanwhile, compared with the giant knotweed rhizome extract group, the grape seed extract group and the arginine group, the mixed group of the three components obviously improves the NO level, reduces the ET-1 and NF-kB levels, has obvious difference (P is less than 0.05), and shows that the effect of the giant knotweed rhizome extract group, the grape seed extract group and the arginine group is obviously greater than that of a single component.
Resveratrol and its glycoside, polydatin, are stilbene compounds naturally produced in plants. Resveratrol and polydatin can be interconverted in plant body. The content of resveratrol and polydatin in giant knotweed rhizome in different producing areas is greatly different. Although polydatin is reported to reduce ET-1 and improve NO content in the prior art, resveratrol and a polydatin extract are found to improve the NO level of vascular endothelial metabolites and reduce the levels of ET-1 and NF-kB for the first time in the application.
Arginine can obviously down-regulate the expression of NF-kappa B, ET-1 and ICAM-1mRNA in the lung, induce apoptosis and promote the recovery of a lung contusion model SD rat prepared by a chest impactor. The intestinal dysfunction of poultry is mainly caused by intestinal mucosa damage and intestinal mucosa permeability increase due to various reasons, and endotoxemia, systemic inflammatory reaction and multiple organ system dysfunction syndrome are induced. NO produced by arginine metabolism is involved in the immune response as a signaling molecule in the maintenance of gut function in poultry, primarily by scavenging free radicals. In the vascular endothelial function maintenance of the present invention, the function of promoting vasodilation with NO is mainly utilized to exert the effect of relieving blood pressure.
Experimental example 2 clinical treatment
In order to demonstrate the therapeutic effect of the composition of the present invention on endothelial dysfunction in blood vessels, the systemic observation of 100 patients with varying degrees of arteriosclerosis aged 45-65 years, 50 cases each of the treatment group and the control group, had excluded those who failed to participate in the experiment, had greater than 70% carotid stenosis, had recently developed thrombi, and were otherwise unsuitable for the experimental situation. All participants had carotid plaques by clinical diagnosis. And recording the age, sex ratio, disease conditions affecting atherosclerosis (hypertension, hyperlipidemia, hyperglycemia), and related living habits (smoking, drinking) of the control group and the treatment group, as shown in tables 2 and 3.
TABLE 2 gender and age of the two groups
TABLE 3 medical history and lifestyle habits of two groups of people
Note: when the medical history and the living condition of the personnel are counted, more than two personnel number are repeatedly counted.
Treatment groups: the composition prepared in example 1 was orally administered 3 times a day with 4 tablets each time for 90 days.
Control group: simvastatin in an amount of 10mg, 1 time a day, for 90 days.
(1) Examination of vascular endothelial function and metabolites
Ultrasonically measuring the distance between intima of the front and rear walls of the brachial artery at the end diastole, recording the base inner diameter D0, inflating and pressurizing the cuff on the right upper arm to about 250mmHg, maintaining for 5min, and recording the inner diameter D1 at 1min after deflation. The average of 3 measurements was taken. The calculation formula of the endothelial-dependent vasodilation function mediated by brachial artery blood flow is EDD ═ D1-D0)/D0 x 100%. In addition, serum ET-1 and NF- κ B were detected by ELISA kits and NO was detected by nitrate reductase, respectively, and the results are shown in Table 4.
TABLE 4 comparison of vascular endothelial cell metabolites before and after treatment
Note: p <0.05 compared to the same group before treatment; after treatment with # P <0.05 compared to control group
The results in Table 4 show that the endothelium-dependent vasodilation function and NO are improved after the treatment with the medicament of the present invention compared to before the treatment, and the improvement of NO is more significant than after the treatment with the control group. ET-1 and NF-kB after treatment of the treatment group are obviously lower than those before treatment, and the treatment effect is more obvious than that after treatment of the control group.
(2) Thickening effect on tunica media
The composition of the present invention is used for judging the therapeutic effect on carotid plaque, referring to the carotid plaque diagnostic standard (2011 edition of Wang Shenming Ministry of angiology published by the national institutes of health). Clinically, carotid intimal-medial thickness (IMT) can be examined by color doppler ultrasound diagnostic to diagnose if carotid plaque is formed. In general, IMT values should be less than 1.0 mm, and if IMT values between 1.0 and 1.2 mm are referred to as intimal thickening, IMT values between 1.2 mm and 1.4 mm may be defined as plaque formation, and if IMT values greater than 1.4 mm, neck vessel stenosis.
Laboratory examination curative effect evaluation standard: the curative effect judgment standard of carotid color Doppler ultrasound refers to color Doppler diagnostics published by people's health publishing agency.
The effect is shown: the IMT value after treatment is reduced by more than or equal to 20 percent compared with that before treatment.
The method has the following advantages: the IMT value after treatment is reduced by 20 percent compared with that before treatment and IMT is more than or equal to 10 percent.
And (4) invalidation: IMT values after treatment do not meet the above criteria.
Statistical treatment is carried out by SPSS software, the measured data obey normal distribution, and differences are found when P is less than 0.05 by adopting t test. Specific clinical results are shown in the table below. Statistical treatment shows that the treatment group and the control group have significant difference (P is less than 0.05), and the treatment effect of the treatment group is significantly higher than that of the control group. Statistical results of the effect of the change in intima-media thickness (IMT) of arterial vessels after treatment with the composition are shown in table 5.
TABLE 5 IMT Change before and after treatment
The results in Table 5 show that the number of significant persons in the treatment group is far greater than that in the control group, the total effective rate is 90 percent, and the effective rate is greater than 88 percent of that in the control group. The composition of the invention has better IMT improvement effect than simvastatin.
(3) Carotid IMT, plaque number, plaque area comparison
Carotid IMT, plaque number, plaque area results before and after treatment were compared in two groups of patients to assess the effect of the composition on carotid plaque.
TABLE 6 comparison of IMT of anterior and posterior carotid artery, plaque number, plaque area before treatment
Note: p <0.05 compared to the same group before treatment; after treatment with control, # P <0.05
Carotid IMT comparison shows:
in 50 cases of the treatment groups, the carotid artery IMT before treatment is 1.55 +/-0.22 mm, the carotid artery IMT after treatment is reduced to 0.98 +/-0.16 mm, and the P is less than 0.05 by t test and has obvious statistical difference compared before and after treatment.
In 50 control groups, the carotid artery IMT before treatment is 1.56 +/-0.23 mm, the carotid artery IMT after treatment is reduced to 1.12 +/-0.24 mm, and compared before and after treatment, the P is less than 0.05 through a t test, and the control groups have obvious statistical difference.
The treated carotid arteries of the two groups, IMT, were 0.98 + -0.16 mm in the treated group and 1.12 + -0.24 mm in the control group, had a P <0.05 by t-test, and had significant statistical differences.
The comparison result of the number of carotid plaque shows that:
in 50 treatment groups, the number of carotid plaque pieces before treatment is 2.56 +/-0.56, the number of carotid plaque pieces after treatment is reduced to 1.47 +/-0.74, and compared before and after treatment, P is less than 0.05, and the treatment groups have significant statistical difference.
In 50 control groups, the number of carotid plaque pieces before treatment is 2.62 +/-0.70, the number of carotid plaque pieces after treatment is reduced to 1.87 +/-0.31, and the P is less than 0.05 by t test compared before and after treatment, so that the control groups have significant statistical difference.
The number of carotid plaques after treatment in the two groups is 1.47 +/-0.74 in the treatment group, 1.87 +/-0.31 in the control group, and the P of the t test is less than 0.05, so that the two groups have significant statistical difference.
The carotid plaque area comparison results show that:
50 cases of treatment groups, the area of carotid plaque before treatment is 16.58 +/-2.01 mm2After treatment, the diameter of the blood vessel decreases to 9.57 +/-1.42 mm2Comparison before and after treatment, t test P<0.05, with significant statistical differences.
In 50 cases of the control group, the area of the carotid plaque before treatment is 16.45 +/-2.23 mm2After treatment, the diameter of the blood vessel decreases to 12.57 +/-1.84 mm2Comparison before and after treatment, t test P<0.05, with significant statistical differences.
The area of carotid plaque in two groups is 9.57 +/-1.42 mm212.57. + -. 1.84mm in the control group2T test P<0.05, with significant statistical differences.
(4) Comparison of internal diameters of carotid arteries
TABLE 7 comparison of internal diameters of carotid artery before and after treatment group
Note: p <0.05 compared to pre-treatment.
The results in table 7 show a significant reduction in carotid artery internal diameter following treatment with the composition of the present invention.
In the clinical experiments, the hematuria routine, the renal function, the electrocardiogram and the like before and after the administration of the medicine are checked and recorded, and no abnormality is found in comparison, so that the traditional Chinese medicine composition has no toxic or side effect and high safety. After the composition is used, the treatment group patients not only remarkably increase the NO level and reduce the expression of metabolites of endothelial cells such as ET-1, NF-kB and the like, but also can improve the endothelium-dependent vasodilation function to a certain degree. Meanwhile, the carotid tunica media thickness, the plaque number and the plaque area of the patient are all reduced, the carotid tunica media thickness, the plaque number and the plaque area are all significantly different from the ratio before treatment, and the treatment group is also significantly different from the control group. In conclusion, the composition can effectively improve the function of the vascular endothelial cells, has no toxic or side effect, and has wide application value.
It should be noted that, when the present invention relates to a numerical range, it should be understood that two endpoints of each numerical range and any value between the two endpoints can be selected, and since the steps and methods adopted are the same as those in the embodiment, in order to prevent redundancy, the present invention describes a preferred embodiment. While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (10)
1. The composition for improving the function of vascular endothelial cells is characterized by being prepared from the following substances in parts by weight: 10-20 parts of giant knotweed extract, 10-20 parts of grape seed extract and 1-3 parts of arginine.
2. The composition for improving vascular endothelial cell function according to claim 1, wherein the effective component of the polygonum cuspidatum extract is resveratrol, and the content of resveratrol is greater than or equal to 50 wt%.
3. The composition for improving vascular endothelial cell function according to claim 1, wherein the grape seed extract contains procyanidin as an active ingredient, and the content of procyanidin is 95 wt% or more.
4. The composition for improving vascular endothelial cell function according to claim 1, further comprising one or more of ginkgo biloba, notoginseng and salvia miltiorrhiza, wherein the ginkgo biloba, notoginseng and salvia miltiorrhiza are added in an amount of 3-5 parts.
5. The composition for improving the function of vascular endothelial cells according to claim 1, further comprising one or more of hawthorn, fish oil powder and red yeast rice, wherein the addition amount of the hawthorn, the fish oil powder and the red yeast rice is 3-5 parts.
6. The composition for improving the function of vascular endothelial cells according to any one of claims 1 to 5, wherein the composition is prepared into a pharmaceutically acceptable dosage form.
7. The composition for improving vascular endothelial cell function according to claim 6, wherein the pharmaceutical dosage form is tablet, granule or powder.
8. The use of the composition for improving the function of vascular endothelial cells according to claim 1 in the preparation of a medicament for preventing and treating cardiovascular and cerebrovascular diseases.
9. The use of the extract of polygonum cuspidatum as claimed in claim 1 in the preparation of a medicament for improving the function of vascular endothelial cells.
10. Use of a grape seed extract according to claim 1 for the preparation of a medicament for improving vascular endothelial cell function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011623645.2A CN112656874A (en) | 2020-12-30 | 2020-12-30 | Composition for improving function of vascular endothelial cells and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011623645.2A CN112656874A (en) | 2020-12-30 | 2020-12-30 | Composition for improving function of vascular endothelial cells and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112656874A true CN112656874A (en) | 2021-04-16 |
Family
ID=75412208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011623645.2A Withdrawn CN112656874A (en) | 2020-12-30 | 2020-12-30 | Composition for improving function of vascular endothelial cells and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112656874A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695652A (en) * | 2004-05-12 | 2005-11-16 | 陕西爱波卓科技有限责任公司 | High performance oxidation resistant compsn. extracted from plant |
| CN102958362A (en) * | 2010-06-28 | 2013-03-06 | 白藜芦醇合伙人有限责任公司 | Resveratrol-containing compositions and methods of use |
| CN103908532A (en) * | 2013-01-08 | 2014-07-09 | 天津天狮生物发展有限公司 | Anti-oxidation traditional Chinese medicine composition, preparation method and application |
| CN109464552A (en) * | 2019-01-04 | 2019-03-15 | 河南中医药大学 | Compound resveratrol nano-lipid carrier and preparation method thereof and application |
-
2020
- 2020-12-30 CN CN202011623645.2A patent/CN112656874A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695652A (en) * | 2004-05-12 | 2005-11-16 | 陕西爱波卓科技有限责任公司 | High performance oxidation resistant compsn. extracted from plant |
| CN102958362A (en) * | 2010-06-28 | 2013-03-06 | 白藜芦醇合伙人有限责任公司 | Resveratrol-containing compositions and methods of use |
| CN103908532A (en) * | 2013-01-08 | 2014-07-09 | 天津天狮生物发展有限公司 | Anti-oxidation traditional Chinese medicine composition, preparation method and application |
| CN109464552A (en) * | 2019-01-04 | 2019-03-15 | 河南中医药大学 | Compound resveratrol nano-lipid carrier and preparation method thereof and application |
Non-Patent Citations (4)
| Title |
|---|
| 王亚运等: "虎杖苷的药理作用研究进展", 《医学综述》 * |
| 胡云峰主编: "《葡萄实用加工技术》", 31 March 2010, 天津科技翻译出版公司 * |
| 薛亮主编: "《血管年轻心脑健康》", 30 June 2015, 人民军医出版社 * |
| 郭金英等: "葡萄籽超微粉对高血脂金黄地鼠血浆NO、ET-1和C反应蛋白的影响", 《食品科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7381435B2 (en) | Composition for treating hepatitis C | |
| CN101406688B (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| JP6977053B2 (en) | A composition for the prevention or treatment of obesity or a metabolic syndrome caused by obesity containing formic acid or a pharmaceutically acceptable salt thereof as an active ingredient. | |
| HASIMUN | Supplementation of Carica papaya leaves (Carica papaya L.) in nori preparation reduced blood pressure and arterial stiffness on hypertensive animal model | |
| JP7071764B2 (en) | Chinese herbal medicine composition for treating cardiovascular disease or cerebrovascular disease, its preparation method and use | |
| CN112656874A (en) | Composition for improving function of vascular endothelial cells and application thereof | |
| CN103735550B (en) | A kind of pharmaceutical composition and application thereof for the treatment of chronic kidney disease myocardial damage | |
| WO2006016682A1 (en) | Ameliorant for blood vessel elasticity and use thereof | |
| CN112807292B (en) | Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| JP2005350450A (en) | Drug or food for prophylaxis/treatment of circulatory disorder and lifestyle-related disease | |
| CN113952377A (en) | Traditional Chinese medicine composition for treating qi deficiency syndrome and preparation method and application thereof | |
| WO2020004585A1 (en) | Composition for improving vascular endothelical function or improving blood flow in peripheral blood vessels | |
| CN102895300A (en) | Traditional Chinese medicine compound capsule for reducing blood sugar, blood fat and blood pressure and preparation method thereof | |
| JP2023505620A (en) | Chinese herbal composition and its production method and use | |
| KR100595459B1 (en) | Composition for inhibiting obesity | |
| KR20040003888A (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| David et al. | Journal of Biological Pharmaceutical And Chemical Research, 2023, 10 (2): 39-49 | |
| CN112336830B (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
| WO2012053667A1 (en) | USE OF β-GLUCAN DELAYING THE BIOSYNTHESIS OF YEAST AND MOLD UNDER ANAEROBIC CONDITION | |
| Hyun-Jung et al. | Berberine for Appetite Suppressant and Prevention of Obesity | |
| JP2006241118A (en) | Hypotensive agent and food and beverage | |
| CN112043748A (en) | A Chinese medicinal tea for adjuvant treatment of hypertension, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210416 |